» Articles » PMID: 25140799

MiR-203 Suppresses the Proliferation and Migration and Promotes the Apoptosis of Lung Cancer Cells by Targeting SRC

Overview
Journal PLoS One
Date 2014 Aug 21
PMID 25140799
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

SRC, also known as proto-oncogene c-Src, is a non-receptor tyrosine kinase that plays an important role in cancer progression by promoting survival, angiogenesis, proliferation, and invasion pathways. In this study, we found that SRC protein levels were consistently upregulated in lung cancer tissues, but that SRC mRNA levels varied randomly, suggesting that a post-transcriptional mechanism was involved in SRC regulation. Because microRNAs (miRNAs) are powerful post-transcriptional regulators of gene expression, we used bioinformatic analyses to search for miRNAs that potentially target SRC. We identified specific targeting sites for miR-203 in the 3'-untranslated region (3'-UTR) of SRC. We then experimentally validated miR-203 as a direct regulator of SRC using cell transfection and luciferase assays and showed that miR-203 inhibited SRC expression and consequently triggered suppression of the SRC/Ras/ERK pathway. Finally, we demonstrated that the repression of SRC by miR-203 suppressed the proliferation and migration and promoted the apoptosis of lung cancer cells. In summary, this study provides the first clues regarding the role of miR-203 as a tumor suppressor in lung cancer cells through the inhibition of SRC translation.

Citing Articles

The Role of microRNAs in Gene Expression and Signaling Response of Tumor Cells to an Acidic Environment.

Riemann A, Rauschner M, Reime S, Thews O Int J Mol Sci. 2023; 24(23).

PMID: 38069241 PMC: 10707721. DOI: 10.3390/ijms242316919.


Identification and functional validation of SRC and RAPGEF1 as new direct targets of miR-203, involved in regulation of epidermal homeostasis.

Golebiewski C, Gastaldi C, Vieu D, Mari B, Rezzonico R, Bernerd F Sci Rep. 2023; 13(1):14006.

PMID: 37635193 PMC: 10460794. DOI: 10.1038/s41598-023-40441-w.


Noncoding RNAs in apoptosis: identification and function.

Tuncel O, Kara M, Yaylak B, Erdogan I, Akgul B Turk J Biol. 2023; 46(1):1-40.

PMID: 37533667 PMC: 10393110. DOI: 10.3906/biy-2109-35.


A TGF-β-responsive enhancer regulates SRC expression and epithelial-mesenchymal transition-associated cell migration.

Noshita S, Kubo Y, Kajiwara K, Okuzaki D, Nada S, Okada M J Cell Sci. 2023; 136(15).

PMID: 37439249 PMC: 10445741. DOI: 10.1242/jcs.261001.


Study on the mechanism of action of on hepatocellular carcinoma based on network pharmacology and bioinformatics.

Yang A, Liu H, Yang Y Front Pharmacol. 2023; 13:1072547.

PMID: 36699068 PMC: 9869961. DOI: 10.3389/fphar.2022.1072547.


References
1.
Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

2.
Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin Y . pp60c-src activation in lung adenocarcinoma. Eur J Cancer. 2003; 39(10):1447-55. DOI: 10.1016/s0959-8049(03)00276-4. View

3.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

4.
Rothschild S, Gautschi O, Haura E, Johnson F . Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010; 11(4):238-42. DOI: 10.3816/CLC.2010.n.030. View

5.
Johnson F, Gallick G . SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem. 2007; 7(6):651-9. DOI: 10.2174/187152007784111278. View